NASDAQ:ARDS

Aridis Pharmaceuticals Stock Forecast

etoro logo Buy ARDS
*Your capital is at risk
$0.0002
+0 (+0%)
At Close: Jun 22, 2026
Add ARDS to Watchlist?
Some Reasons Why To Add ARDS:
  • Lower volatility than the market (beta -26.04)
  • +100.0% price growth over the last year
  • Strong return on equity of 164.7%

ARDS Performance

FAQ

What is the symbol for Aridis Pharmaceuticals Inc. Stock and on which exchange is it traded?
The symbol for Aridis Pharmaceuticals Inc. is ARDS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Aridis Pharmaceuticals Inc. Stock?
Aridis Pharmaceuticals Inc. holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Aridis Pharmaceuticals Inc. Stock?
Aridis Pharmaceuticals Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Aridis Pharmaceuticals Inc. Stock.

What's the current price of Aridis Pharmaceuticals Inc. Stock?
As of the end of day on the Jun 22, 2026, the price of an Aridis Pharmaceuticals Inc. (ARDS) share was $0.0002.

What is the 52-week high and low for Aridis Pharmaceuticals Inc. Stock?
The 52-week high for Aridis Pharmaceuticals Inc. Stock is $0.0031 and the 52-week low is $0.0001000000.

What is the market capitalization of Aridis Pharmaceuticals Inc. Stock?
As of the Jun 22, 2026, the market capitalization of Aridis Pharmaceuticals Inc. is 138.179K.

When is the next earnings date for Aridis Pharmaceuticals Inc.?
The upcoming earnings date for Aridis Pharmaceuticals Inc. is Aug 19, 2026.
Click to get the best stock tips daily for free!
ABOUT ARIDIS PHARMACEUTICALS INC.
Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-32...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.29% Jun 10
PHM
$118.49
6.02% Jun 10
EAT
$140.46
17.09% Jun 05
E
ETD
$20.67
3.19% Jun 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE